In simple words: This blood test measures three substances in your blood that can indicate liver disease.A computer program then uses these results, along with other information about you, to calculate your risk of developing liver scarring (fibrosis) or other liver problems within the next five years. This can help doctors monitor your liver health and decide on the best course of treatment.

Using a serum specimen, this test uses immunoassays to evaluate the levels of three liver disease biomarkers: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1). As a multianalyte assay with algorithmic analysis (MAAA), the service includes an algorithmic analysis using patient data and lab test results to report a risk score for liver fibrosis and liver-related clinical events within five years. The lab analyst performs immunoassays on the patient’s serum for the three biomarkers. This MAAA includes the analytical services to produce test results and uses those results, along with patient data, for an algorithmic analysis that reports the findings as a probability or risk score. Using the serum levels of the three measured biomarkers plus patient and clinical data, the algorithm provides a probability score for liver disease, known as an ELF (enhanced liver fibrosis) score. This test is used for screening and follow-up of patients with liver disease, offering a less invasive alternative to a liver biopsy while providing comparable information regarding the likelihood of developing liver fibrosis or liver-related clinical events within five years.

Example 1: A patient with non-alcoholic fatty liver disease (NAFLD) is monitored for disease progression using the ELF score calculated by 81517., A patient with chronic hepatitis C undergoes testing with 81517 to assess the risk of developing liver fibrosis., A patient with an indeterminate FIB-4 score undergoes reflex testing with 81517 for further risk stratification.

Documentation should include the patient's medical history, clinical presentation, and the rationale for ordering the test, along with the serum test results and the calculated ELF score.

** The ELF score is a valuable tool for the non-invasive assessment of liver fibrosis risk and can aid in clinical decision-making regarding further investigation, treatment, and monitoring of liver disease. iFrameAI resources can be used for up-to-date information.